Kennedy’s health overhaul: A dangerous gamble for Australia’s regulatory future

The appointment of Robert F. Kennedy Jr. as the new U.S. Secretary of Health and Human Services has raised serious concerns in Australia about the future of medical research and access to innovative health technologies.

Kennedy Jr. has already pledged to launch an extensive investigation into the safety of widely prescribed mental health and weight-loss medicines, including selective serotonin reuptake inhibitors (SSRIs), antipsychotics, antidepressants, mood stabilisers, stimulants, and weight-loss drugs. His review aims to uncover potential risks associated with their use, a move that could have far-reaching implications for regulatory frameworks worldwide.

A long-time critic of SSRIs, Kennedy made a striking comparison at his confirmation hearing, stating, “I know people, including members of my family, who’ve had a much worse time getting off of SSRIs than they have getting off of heroin.” His comments have reignited debates on the safety and dependency risks of this class of medicines that includes Prozac (fluoxetine), Zoloft (sertraline), and Lexapro (escitalopram).

Now at the helm of 13 U.S. health agencies – including the Centres for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) – Kennedy’s influence extends beyond U.S. borders. His controversial stance on vaccines and alternative therapies is raising concerns about how regulatory decisions in the U.S. could impact health technology approvals and public health policies in Australia.

The Therapeutic Goods Administration (TGA) often aligns with FDA standards, given their shared involvement in international regulatory groups such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the Medical Device Regulators Forum (IMDRF). As a result, changes in U.S. regulatory policy can have direct consequences for Australia, particularly in health technology approvals, clinical trial requirements, Good Manufacturing Practice (GMP) regulations, and drug safety monitoring.

For instance, the FDA’s breakthrough therapy designation (BTD), which accelerates drug approvals for serious illnesses or unmet medical needs, has been pivotal in expediting access to innovative treatments in both the U.S. and Australia. Similarly, the TGA frequently refers to FDA safety alerts, black box warnings, and recalls when making decisions about the Australian market.

However, Kennedy’s plan to downsize the FDA and reduce the agency’s reliance on industry fees threatens to destabilise the regulatory environment, potentially delaying the approval of new health technologies. Such disruption would delay access to life-saving treatments, affecting not just the U.S. but also Australia, where 90% of health technologies are imported from global companies.

Kennedy has long been a vocal critic of vaccines. As the founder of the anti-vaccine group Children’s Health Defence, he has promoted theories linking vaccines to autism. His appointment has already rattled the pharmaceutical sector, with stock prices of vaccine manufacturers like Moderna and Pfizer taking a hit following Trump’s announcement of his appointment.

Kennedy’s scepticism extends to a wide array of treatments. He has accused the FDA of suppressing alternative therapies, stating that it has blocked access to “psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, nutraceuticals and anything else that advances human health and can’t be patented.”

He said that those who were “part of this corrupt system” should be prepared to “pack your bags”.

Adding to the growing alarm, Kennedy has proposed an eight-year pause on infectious disease research to shift focus toward chronic diseases and alternative therapies. Such a move could hinder the development of innovative diagnostics and treatments for emerging health threats.

For Australia’s healthcare sector, Kennedy’s appointment is not just a U.S. issue – it is a global concern. With the nation’s regulatory systems closely tied to the FDA, any major shift in U.S. health policy would have profound consequences for the timely approval of innovative health technologies and the future of medical research.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.